BeOne Medicines AG (BEIGF)

Market Cap	35.17B +47.6%
Revenue (ttm)	5.34B +40.2%
Net Income	286.93M
EPS	2.47
Shares Out	n/a
PE Ratio	122.56
Forward PE	55.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	104,000
Average Volume	5,628
Open	24.92
Previous Close	24.92
Day's Range	24.92 - 24.92
52-Week Range	13.68 - 24.92
Beta	0.52
RSI	63.58
Earnings Date	Feb 26, 2026

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: OTCMKTS
• Ticker Symbol: BEIGF